01
Clinical
TG4050 Neoantigen Vaccine Shows 100% Three-Year Disease-Free Survival in Phase 1 Head and Neck Cancer Trial - Oncodaily
Transgene and NEC Corporation have reported sustained 100% three-year disease-free survival (DFS) among patients treated with the individualized neoantigen therapeutic vaccine TG4050 in the Phase 1 portion of a randomized Phase 1/2 trial in resected, locally advanced HPV-negative…